Who Paid My Doc
Cleviprex
Drug Cardiovascular
NDC 10122-610-10
General payments
$3,404,224
Research payments
$0
Through program year 2025, $3,404,224 in general payments and $0 in research payments were reported against Cleviprex (Cardiovascular).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $492,083 | 4,408 |
| 2024 | General | $846,907 | 4,922 |
| 2023 | General | $521,651 | 4,953 |
| 2022 | General | $496,098 | 6,531 |
| 2021 | General | $367,193 | 7,336 |
| 2020 | General | $145,670 | 692 |
| 2019 | General | $534,621 | 4,595 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 76 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
33,437 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.